The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the ...
Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.
Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line ...
Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott’s Lingo offers real-time glucose tracking to improve health and wellness. See my hands-on experience and if it’s worth ...
Stifel raised the firm’s price target on Abbott (ABT) to $135 from $130 and keeps a Buy rating on the shares. The firm views Abbott’s Q4 ...
For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...
CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.
Abbott has received an innovation award for Lingo, its first consumer biowearable over-the-counter device designed to support ...